JPRN-UMIN000008505已完成4 期
A prospective comparison of epoetin beta pegol and darbepoetin alpha in the variability of blood pressure in pre-dialysis chronic kidney disease (CKD). - A prospective comparison of epoetin beta pegol and darbepoetin alpha in the variability of blood pressure in pre-dialysis chronic kidney disease (CKD).
Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine0 个研究点目标入组 36 人开始时间: 2012年7月23日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 36
研究概览
简要总结
Office/ambulatory BP, renal function, and other parameters were not significantly different between groups. Although office/ambulatory BP profiles had not worsened after 24 weeks of ESA treatment, more than half of the patients required an increase in the antihypertensive agent dose.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.Severe hypertension(diastolic blood pressure is over 100 mmHg within 12 weeks) 2.Congestive heart failure(NYHA class3, 4) 3.Pregnant women and/or women who are suspect of pregnancy 4.History or complication of cardiac infarction, pulmonary embolism or symptomatic cerebral infarction 5.History of hypersensitivity to epoetin beta pegol and/or darbepoetin alpha 6.Patients with malignancy, severe infection, systemic blood disease(MDS, etc.), hemolytic anemia or hemorrhagic disease 7.Administration of anabolic steroids, testosterone enanthate or mepitiostane within 12 weeks 8.Erythrocyte transfusion within 16 weeks 9.Patients who will plan to undergo a severe bleeding surgery 10.Patients judged as inappropriate for the study
研究者
相似试验
已完成
不适用
Effect of epoetin beta pegol treatment on renal anemia and blood pressure control in non-dialytic CKD patientsnon-dyalitic chronic kidney disease (CKD)JPRN-UMIN000009449Kurashiki Central Hospital100
已完成
不适用
Efficacy of erythropoietin beta pegol assessment study with kidney diseases.renal anemiaJPRN-UMIN000007494Kyoto University Graduate School of Medicine100
尚未招募
不适用
The influence of administration of epoetin beta pegol (CERA) and saccharated ferric oxide on erythroferron and hepcidin of hemodialyzed patientsHemodialyzed patients with renal anemiaJPRN-UMIN000016552Hyogo College of Medicine50
已完成
3 期
Effect of Epoetin Beta on Renal Function Within 30 Days Following a Kidney TransplantKidney FailureNCT00815867Centre Hospitalier Universitaire, Amiens108
进行中（未招募）
不适用
ffet de l’Epoetin Beta sur la fonction rénale et l’anémie dans les trente jours suivant une transplantation rénale - Etude Neo-PDGFPatients insuffisants rénaux chroniques, au stade terminal de leur affection, traités en dialyse. Patients, hommes ou femmes, agés de 18 à 75 ans, devant bénéficier d'une transplantation rénale à partir d'un donneur en coma dépassé et étant à risque de récupération lente de la fonction du greffon. Randomisés pour recevoir 4 injections de 30000 UI de NeoRecormon (Epoetin bêta) avant le déclampage, 12 heures après la greffe et à J7 et J14 (Groupe A), ou aucun traitement (Groupe B).MedDRA version: 9.1Level: LLTClassification code 10058116Term: Nephrogenic anaemiaMedDRA version: 9.1Level: LLTClassification code 10009120Term: Chronic renal failure anaemiaEUCTR2007-002562-35-FRCHU AMIENS